News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Natco Pharma intends to defend the matter accordingly
Submission based on results from pivotal phase III trial showing all primary endpoints met
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
This acquisition enables MTD to open new, strategic markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
